These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from May 1 through May 7, 2025. Source: VerityData

Activist Filings

WEX $(WEX)$ Impactive Capital lowered its stake in the corporate payment-processing company to 2,395,253 shares. Impactive Capital did so through the sale of 190,882 WEX shares from March 26 through April 3, 2025, at per share prices ranging from $145.43 to $163.01, after buying 2,088 WEX shares on March 7 at $154.41 apiece. On May 2, Impactive Capital issued an open letter to WEX's board, requesting that an Impactive representative be added to bring a "much-needed shareholder perspective" following a period of deteriorating performance through the end of 2024.

Accordingly, Impactive has also recommended that shareholders vote against the appointment of incumbent directors Jack VanWoerkom, Melissa Smith, and James Neary at the firm's next annual meeting.

Following the latest sales, Impactive Capital continues to own 7% of WEX's outstanding stock. Shares of WEX have lost approximately 30.8% of their value since the beginning of this year.

Original Filings

Acelyrin$(SLRN)$ Madison Avenue Partners disclosed a new position in the clinical-stage biopharmaceutical company of 5,089,260 shares. Madison Avenue purchased 4,054,748 of those shares from March 3 through April 30, 2025, at per share prices ranging from $2.10 to $2.74, and offset those purchases through the sale of 120,622 Acelyrin shares from April 4 to April 7 at $2.41 to $2.57.

Following the latest purchases, Madison Avenue Partners owns 5.1% of Acelyrin's outstanding stock. Shares of Acelyrin have lost approximately 26.7% of their value since the beginning of this year.

Alpha Tau Medical (DRTS) Oramed Pharmaceuticals disclosed a new position in the clinical-stage oncology therapeutics company of 14,110,121 shares. Oramed Pharmaceuticals purchased those shares on April 28, 2025, at a purchase price of $2.61 apiece in connection with the company's registered direct offering.

Following the latest purchases, Oramed Pharmaceuticals owns 19.99% of Alpha Tau Medical's outstanding stock. Shares of Alpha Tau Medical have lost roughly 12.3% of their value since the beginning of this year.

Increases in Holdings

Algoma Steel Group$(ASTL)$ Maple Rock Capital Partners raised its stake in the integrated steel producer to 7,552,617 shares. Maple Rock Capital Partners did so through the purchase of 1,460,526 Algoma Steel Group shares from March 10 through May 5, 2025, at per share prices ranging from $4.91 to $6.27.

Following the latest purchases, Maple Rock Capital continues to own 7.2% of Algoma Steel Group's outstanding stock. Shares of Algoma Steel Group have lost approximately 45.7% since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 09, 2025 18:18 ET (22:18 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.